The SFDA Approves the First Gene Therapy for Hemophilia (B) in Saudi Arabia

News Healthcare & Pharma General Updates

Date: 11th Feb, 2025 Source: Saudi Food and Drug Authority (SFDA) Country: Saudi Arabia Original Source

Brief

On 11/02/2025, the Saudi Food and Drug Authority (SFDA) issued an update regarding The SFDA Approves the First Gene Therapy for Hemophilia (B) in Saudi Arabia. This approval marks a significant milestone in the Kingdom's efforts to provide advanced treatment options for patients with life-threatening genetic disorders. The registered gene therapy, Hemgenix, utilizes an adeno-associated virus viral vector to deliver functional factor IX genes, promoting clotting and controlling bleeding.

This content is restricted.

Highlights content goes here...

This content is restricted.

Saudi Food and Drug Authority (SFDA)

RADA.AI

Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?

Suggested

The SFDA Approves the First Gene Therapy for Hemophilia (B) in Saudi Arabia

Brief

Saudi Food and Drug Authority (SFDA)

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Verify Email

Tell us more about yourself

Select your work area

Select your country

All set.

The SFDA Approves the First Gene Therapy for Hemophilia (B) in Saudi Arabia

Brief

Saudi Food and Drug Authority (SFDA)

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Verify OTP

Enter your Email

Verify Email

Tell us more about yourself

Select your work area

Select your country

All set.